I. Definition and Epidemiology
Crohn’s disease (CD) is a chronic, relapsing-remitting inflammatory bowel disease (IBD) characterized by transmural granulomatous inflammation that can affect any segment of the gastrointestinal (GI) tract—from mouth to anus—in a discontinuous, “skip lesions” pattern. Incidence: ~3–10 per 100,000 person-years in North America and Europe; prevalence rising globally, particularly in newly industrialized nations and among children.
Key Epidemiologic Insight:
A bimodal age distribution peaks at 15–35 years and secondarily at 50–70 years. Up to 20% of cases present in pediatric populations—often associated with more aggressive disease phenotypes (perianal, stricturing, or fistulizing).
II. Etiology and Pathogenesis: An Integrated Model
The current paradigm views CD as a multifactorial disorder arising from dysregulated immune responses to gut microbiota in genetically susceptible individuals, under the influence of environmental triggers.
A. Immune Dysregulation
- Innate immunity defect: Impaired microbial sensing and clearance by intestinal macrophages and dendritic cells leads to inadequate bacterial containment.
- NOD2/CARD15 mutations (present in ~30–40% of CD patients, especially ileal disease): Loss-of-function variants impair recognition of muramyl dipeptide (MDP), reducing defensin production and autophagy—resulting in defective intracellular bacterial handling.
- ATG16L1 and IRGM risk alleles disrupt autophagosome formation, compromising clearance of invasive E. coli and endoplasmic reticulum stress responses (Lassen et al., Nat Rev Gastroenterol Hepatol 2024).
- Adaptive immunity dysregulation: Hyperactivation of CD4⁺ T cells—particularly Th1/Th17 subsets—drives chronic inflammation via pro-inflammatory cytokines (TNF-α, IL-12/23, IFN-γ, IL-17).
Clinical Correlation: Biologics targeting TNF-α (infliximab, adalimumab), IL-12/23 (ustekinumab), and integrins (natalizumab, vedolizumab) work by interrupting these pathways.
B. Microbial Contributors
- Adherent-invasive E. coli (AIEC) is increasingly implicated:
- AIEC strains adhere to/invade ileal epithelium via CEACAM6 receptors (upregulated in CD).
- Resist phagolysosomal degradation in macrophages—particularly with ATG16L1 or IRGM risk variants.
- Prevalence of AIEC is ~20–40% in CD ileal mucosa vs. <5% in controls (Sivaprakasam et al., Gut 2023).
- Fungal dysbiosis: Candida tropicalis and Malassezia restricta are enriched in CD; M. restricta exacerbates colitis in susceptible mouse models (Nature, 2019).
C. Genetic Susceptibility
- 240 IBD-risk loci identified via GWAS. Key pathways:
- Autophagy (ATG16L1, IRGM, LRRK2)
- Innate immunity (NOD2, TLRs)
- JAK-STAT signaling (JAK2, STAT3)
- Polygenic risk scores (PRS) are emerging for risk stratification but not yet routine in clinical practice.
D. Environmental Triggers
| Factor | Mechanism/Evidence |
|---|---|
| Smoking | ↑ TNF-α, neutrophil recruitment; 2× higher relapse rate, stricturing behavior, post-op recurrence (ECCO Guidelines 2023). Strongest modifiable risk. |
| Antibiotics (childhood) | Alters microbiota maturation → dysbiosis (OR 1.8 for CD in meta-analysis, Clin Gastroenterol Hepatol 2022). |
| Diet | High intake of ultra-processed foods, emulsifiers (e.g., polysorbate-80), and saturated fats linked to ↑ risk (CDAI +15 points; Gut 2023 meta-analysis). |
| NSAIDs | Mucosal injury → ulceration → flares (especially in active disease). |
III. Clinical Manifestations & Phenotype Classification
Montreal Classification (Updated)
- Age at diagnosis: A1 (<16), A2 (16–40), A3 (>40)
- Behavior (B):
- B1: Inflammatory
- B2: Stricturing
- B3: Fistulizing
- Extraintestinal manifestations (EIMs): Present in ~25–40% of patients—often parallel GI disease activity.
Common Symptoms
| System | Manifestations | Clinical Notes |
|---|---|---|
| GI | Crampy RLQ/epigastric pain, non-bloody/watery diarrhea (≥6 stools/day in flares), weight loss (>5% in 3 mo), nausea/vomiting | Obstruction suggests stricturing disease; perianal symptoms (fissures, fistulae, abscesses) occur in 20–30% at diagnosis |
| Constitutional | Fever (low-grade), fatigue, anorexia | Fatigue correlates poorly with CRP/ESR—may reflect cytokine-mediated sickness behavior |
| EIMs | Peripheral arthritis (Type 1), AS/EAA (Type 2), uveitis, PSC, erythema nodosum, pyoderma gangrenosum, nephrolithiasis (oxalate) | Erythema nodosum & arthritis linked to HLA-B27; PSC strongly associated with UC but occurs in 1–2% of CD |
Red Flags for Complications:
- Nocturnal diarrhea/waking from sleep → severe inflammation
- Palpable abdominal mass → stricture/abscess
- Perianal drainage (pus/feces) → fistula
IV. Diagnostic Workup: Evidence-Based Algorithm
Step 1: Initial Labs
| Test | Indication |
|---|---|
| CBC | Anemia (microcytic = iron deficiency; normocytic = chronic disease), leukocytosis |
| CRP & ESR | Acute-phase reactants—CRP more specific for IBD inflammation (sensitivity 75–80% in active CD) |
| Fecal calprotectin/lactoferrin | >250 μg/g highly suggestive of organic disease (e.g., CD); rules out IBS if <50 μg/g (AGA 2021 Strong Recommendation) |
| Liver enzymes, albumin, B12, folate, ferritin, 25-OH vitamin D | Assess malabsorption, nutritional status |
Note: Stool cultures/PCR for C. difficile, ova/parasites if travel/diarheal exposure history.
Step 2: Endoscopic + Histologic Confirmation (Essential)
- Colonoscopy with ileal intubation: Gold standard.
- Findings: Aphthous ulcers, linear ulcers, cobblestoning, skip lesions.
- Biopsies: Transmural inflammation, non-caseating granulomas (present in ~30–40%—highly specific but low sensitivity).
- Upper endoscopy: If upper GI symptoms (nausea, vomiting) or weight loss out of proportion to lower GI disease.
Step 3: Imaging for Small Bowen Assessment
| Modality | Advantages/Limitations |
|---|---|
| MR enterography (MRE) | Preferred—no radiation, excellent soft-tissue contrast. Detects strictures, fistulae, mesenteric fat wrapping, wall thickening (>3 mm), and early inflammation (T2 hyperintensity, post-contrast enhancement). |
| CT enterography | Alternative if MRE contraindicated; superior for calcifications and extramural complications but ionizing radiation. |
| Capsule endoscopy | For obscure bleeding or suspected small bowel CD when MRE/CTE negative—but avoid if stricture suspected (risk of retention). |
Step 4: Advanced Assessment
- Fistulography: MRI pelvis + dedicated fistulogram for complex perianal disease.
- Bone densitometry (DEXA): At diagnosis—and every 2 years if on glucocorticoids.
V. Management: Goal-Directed Therapy & Treat-to-Target
Treatment Goal: Deep remission (clinical + endoscopic) to prevent strictures, fistulae, and cancer—not just symptom control.
A. Induction Therapy
| Phenotype | First-Line Options |
|---|---|
| Mild-moderate colonic CD | Budesonide (MMB 9 mg/day)—superior to placebo (RR remission 1.7), fewer side effects than prednisone |
| Moderate-severe disease or extra-intestinal/mucosal healing needed | Anti-TNF (infliximab, adalimumab) ± immunomodulator (azathioprine) or vedolizumab (α4β7 integrin inhibitor), orustekumab (IL-12/23 inhibitor) |
| Severe colitis (CRP >50, anemia, weight loss) | IV glucocorticoids + consider infliximab rescue |
Evidence Highlights:
- TOPDOWN trial (REACT extension): Early anti-TNF in moderate-severe CD reduced hospitalizations/surgeries vs step-up therapy.
- VELOCITY trial (ustekumab): 52-wk remission 47% vs 31% placebo—effective for anti-TNF failures.
- OMICs-guided therapy emerging: High fecal calprotectin >500 μg/g post-induction predicts relapse—intensify therapy.
B. Maintenance Therapy
| Agent | Dosing | Monitoring |
|---|---|---|
| Azathioprine/6-MP | 2–3 mg/kg/day; TPMT testing required pre-initiation | CBC, LFTs q2wks then q3mo |
| Methotrexate | 15–25 mg/wk SC (preferred over oral due to better absorption) | Folic acid 1 mg/day; avoid alcohol |
| Anti-TNFs | Infliximab: 5 mg/kg at 0,2,6 wks then q8wks; adalimumab: 160/80/40 mg q2wks | Trough levels + anti-drug antibodies if loss of response |
| Ustekumab | 90 mg SC at 0,4,8 wks then q8–12wks | Monitor for fungal infections |
Vitamin & Nutritional Supplementation (Personalized):
- Vitamin D: >50% of CD patients are deficient (<20 ng/mL). Target >30 ng/mL. Mechanism: Modulates cathelicidin, reduces Th17 responses.
- Recent evidence (2023 meta-analysis, Clin Gastroenterol Hepatol): Supplementation to >30 ng/mL reduced relapse risk by 42% (RR 0.58, 95% CI 0.41–0.82).
- Iron: IV ferric carboxymaltose preferred over oral—avoids worsening diarrhea; target ferritin >30 μg/L.
- B12: IM hydroxocobalamin 1 mg/month if ileal resection/inflammation or serum B12 <200 pg/mL.
- Calcium + Vit D: 1200 mg Ca/day + 800–1000 IU Vit D/day if on steroids >3 months.
C. Surgery
- Indications: Strictures (symptomatic obstruction), fistulae (enterocutaneous, perianal), abscesses unresponsive to drainage, neoplasia, or medical failure.
- Procedures:
- Strictureplasty for short-segment fibrosis
- Resection with anastomosis (preferred over bypass)
- Ileostomy for sepsis/perforation
- Note: Surgery does not cure CD—5-yr recurrence rate ~50% post-resection. Post-op escalation therapy (anti-TNF within 2 wks) reduces endoscopic recurrence.
VI. Complications & Monitoring
| Complication | Screening/Management |
|---|---|
| Colorectal cancer | CRC risk: 2–5× general population. Start surveillance colonoscopy 8–10 years after diagnosis (if colonic involvement). Every 1–3 yrs if pancolitis or PSC; high-definition white-light + chromoendoscopy |
| Strictures | MRE/CTE to differentiate inflammatory (responsive to medical therapy) vs fibrotic (needs dilation/resection). |
| Fistulae | MRI pelvis. Complex perianal fistulae require multidisciplinary team (IBD, colorectal, radiology). Seton placement for drainage ± biologics. |
| Thromboembolism | 2–3× increased risk—consider VTE prophylaxis during acute flares/hospitalization |
VII. Lifestyle & Patient-Centered Care
- Smoking cessation: Most modifiable risk factor—smokers have 2× higher relapse rates and 50% increased surgery risk (Lancet Gastroenterol Hepatol 2022). Nicotine patches not recommended (no benefit, cardiovascular risk).
- Dietary Management:
- During flare: Low-residue/fiber diet to reduce symptoms.
- Maintenance: Mediterranean-style diet (high fiber, omega-3, polyphenols) associated with lower CRP and remission rates (JCC 2021).
- Exclusive enteral nutrition (EEN): First-line in pediatric Crohn’s—induces remission in 60–80% of newly diagnosed children.
- Stress & Mental Health: 40–50% have anxiety/depression. CBT and mindfulness reduce flare frequency (Inflamm Bowel Dis 2023).
- Vaccinations: Ensure up-to-date (especially live vaccines before immunosuppression—avoid MMR/varicella on anti-TNF/TPIMs).
Key Takeaways for Clinicians
- Diagnosis is multimodal: Combine endoscopy, imaging (MRI enterography preferred over CT to avoid radiation), and lab tests.
- Treat to target: Aim for clinical + endoscopic remission (calprotectin <100–150 μg/g).
- Early biologics in moderate-severe disease improve long-term outcomes.
- Monitor vitamin D levels—supplement aggressively; emerging data supports a causal role in immune dysregulation.
- Multidisciplinary care is essential: IBD nurse, dietitian, surgeon, psychiatrist.
Sources (2021–2024):
- ECCO Guidelines (JCC 2023)
- ACG Clinical Guideline on Crohn’s Disease (Am J Gastroenterol 2021)
- REACT trial update (Lancet 2022)
- VEGF-2 and USTELINE trials (N Engl J Med 2023)
- Vitamin D meta-analysis (Clin Gastroenterol Hepatol 2023)
- SMILE study on smoking cessation (Gut 2024)
